Use of progestin-only drospirenone-based pills in hyperandrogenic women with polycystic ovary syndrome
This study showed that a 6-month drospirenone (DRSP)-only therapy significantly reduced hyperandrogenism symptoms, such as acne and hirsutism, in PCOS patients. It also lowered 17-OH-progesterone levels and showed a trend of reduced CRP values. Bleeding patterns were consistent with those in existing literature. We recommend DRSP-only therapy as a suitable option for PCOS patients with hyperandrogenism who cannot use combined oral contraceptives (COCs), as well as to minimize the metabolic risks of estrogen.
Authors
- Cristina Guerriero (ORCID: https://orcid.org/0000-0003-2067-8081)
- Anna Tropea
- Antonio Lanzone (ORCID: https://orcid.org/0000-0003-4119-414X)
- Rosanna Apa (ORCID: https://orcid.org/0000-0003-0143-9114)
- Monia Ranalli (ORCID: https://orcid.org/0000-0001-7193-8803)
- Giovanna Notaristefano (ORCID: https://orcid.org/0000-0003-1124-6877)
- T. Ghi (ORCID: https://orcid.org/0000-0003-1823-1096)
- Annamaria Merola
- Alice Diterlizzi (ORCID: https://orcid.org/0000-0002-7681-1200)
- Martina Policriti
- Eleonora De Luca (ORCID: https://orcid.org/0000-0003-3893-2869)
- Anastasyia Samasiuk
- Ambra Moricone
Institutions
- Università Cattolica del Sacro Cuore (IT)
- Agostino Gemelli University Polyclinic (IT)
- Istituti di Ricovero e Cura a Carattere Scientifico (IT)
- Sapienza University of Rome (IT)
Publication Details
- Journal
- Archives of Gynecology and Obstetrics
- Published
- 2025-09-10
- DOI
- https://doi.org/10.1007/s00404-025-08083-7
- Primary Topic
- Ovarian function and disorders
- Type
- article
- Field-Weighted Citation Impact
- 0.00